Enterprise Financial Services Corp boosted its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 173.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,260 shares of the company’s stock after buying an additional 800 shares during the period. Enterprise Financial Services Corp’s holdings in Zimmer Biomet Holdings were worth $151,000 as of its most recent filing with the SEC.
Other large investors have also recently added to or reduced their stakes in the company. Park Avenue Institutional Advisers LLC increased its position in shares of Zimmer Biomet Holdings by 1.2% in the first quarter. Park Avenue Institutional Advisers LLC now owns 1,128 shares of the company’s stock valued at $120,000 after buying an additional 13 shares during the last quarter. Regent Investment Management LLC bought a new position in shares of Zimmer Biomet Holdings during the second quarter valued at approximately $217,000. Checchi Capital Advisers LLC increased its position in shares of Zimmer Biomet Holdings by 3.7% in the second quarter. Checchi Capital Advisers LLC now owns 1,832 shares of the company’s stock valued at $221,000 after buying an additional 66 shares during the last quarter. Atria Investments LLC bought a new position in shares of Zimmer Biomet Holdings during the second quarter valued at approximately $238,000. Finally, FirstMerit Bank N A Trustee bought a new position in shares of Zimmer Biomet Holdings during the second quarter valued at approximately $247,000. 88.32% of the stock is currently owned by institutional investors.
Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded down 0.79% during trading on Wednesday, reaching $128.08. The company had a trading volume of 772,296 shares. The firm has a market capitalization of $25.62 billion, a PE ratio of 116.97 and a beta of 0.95. The firm’s 50 day moving average price is $127.95 and its 200 day moving average price is $122.63. Zimmer Biomet Holdings Inc. has a 12-month low of $88.27 and a 12-month high of $133.21.
Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 28th. The company reported $2.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.97 by $0.05. Zimmer Biomet Holdings had a net margin of 1.68% and a return on equity of 16.12%. The business earned $1.93 billion during the quarter, compared to analyst estimates of $1.90 billion. During the same period last year, the business posted $1.58 earnings per share. Zimmer Biomet Holdings’s quarterly revenue was up 65.6% compared to the same quarter last year. Equities research analysts forecast that Zimmer Biomet Holdings Inc. will post $7.97 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 23rd will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.75%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 157.38%.
Several research analysts have commented on ZBH shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $125.00 target price on shares of Zimmer Biomet Holdings in a report on Tuesday, June 21st. Zacks Investment Research raised Zimmer Biomet Holdings from a “hold” rating to a “buy” rating and set a $135.00 target price on the stock in a report on Monday, July 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $143.00 target price (up from $134.00) on shares of Zimmer Biomet Holdings in a report on Monday, July 18th. Barclays PLC lifted their target price on Zimmer Biomet Holdings from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Finally, Citigroup Inc. lifted their target price on Zimmer Biomet Holdings from $91.00 to $95.00 and gave the stock a “sell” rating in a report on Friday, July 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-one have issued a buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Buy” and a consensus price target of $133.57.
In other Zimmer Biomet Holdings news, insider Stuart G. Kleopfer sold 533 shares of the firm’s stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $132.71, for a total transaction of $70,734.43. Following the completion of the transaction, the insider now owns 6,397 shares of the company’s stock, valued at $848,945.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Tony W. Collins sold 1,287 shares of the firm’s stock in a transaction that occurred on Friday, August 12th. The shares were sold at an average price of $129.16, for a total transaction of $166,228.92. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by company insiders.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.